NCT05968599View on ClinicalTrials.gov

A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer

CompletedOBSERVATIONAL
Enrollment

2,731

Participants

Timeline

Start Date

July 24, 2023

Primary Completion Date

February 14, 2025

Study Completion Date

February 14, 2025

Conditions
Prostatic Neoplasms, Castration-Resistant
Interventions
DRUG

Enzalutamide

As provided in real-world setting

DRUG

Abiraterone acetate

As provided in real-world setting

Trial Locations (1)

10001

Pfizer Inc, New York

Sponsors

Lead Sponsor

Pfizer

Collaborators (1)

Astellas Pharma Inc
All Listed Sponsors
collaborator

Astellas Pharma Inc

INDUSTRY

lead

Pfizer

INDUSTRY